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A B S T R A C T
Medical images are an integral part of oncological patient records and they are reviewed by many different
specialists. Therefore, it is important that besides imaging experts, other clinicians are also aware that the
diagnostic value of a scan is influenced by the applied imaging protocol.
Based on two clinical lung cancer trials, we experienced that, even within a study protocol, there is a large
variability in imaging parameters, which has direct impact on the interpretation of the image. These two trials
were: 1) the NTR3628 in which the added value of gadolinium magnetic resonance imaging (Gd-MRI) to
dedicated contrast enhanced computed tomography (CE-CT) for detecting asymptomatic brain metastases in
stage III non-small cell lung cancer (NSCLC) was investigated and 2) a sub-study of the NVALT 12 trial
(NCT01171170) in which repeated 18 F-fludeoxyglucose positron emission tomography (18F-FDG-PET) imaging
for early response assessment was investigated.
Based on the problems encountered in the two trials, we provide recommendations for non-radiology clin-
icians, which can be used in daily interpretation of imaging. Variations in image parameters cannot only in-
fluence trial results, but sub-optimal imaging can also influence treatment decisions in daily lung cancer care,
when a physician is not aware of the scanning details.
1. Introduction
Medical imaging is an essential component of the diagnostic pro-
cedures performed in lung cancer. Next to that, it is also used for re-
sponse assessment. The imaging modalities used in oncology have
evolved from simple X-rays to computed tomography (CT)- and mag-
netic resonance imaging (MRI) scans. Nuclear imaging has innovated by
the introduction of positron-emission tomography (PET) with several
tracers being 18F-fludeoxyglucose (18F-FDG) most frequently used. An
18F-FDG-PET-scan using an integrated PET-CT scanner combined with a
contrast enhanced CT (CE-CT) is nowadays a standard staging tech-
nique in thoracic oncology. Due to ongoing technological innovations,
the sensitivity and specificity of these modalities have significantly
improved. However, many factors, as patient preparation, image ac-
quisition and reconstruction parameters affect the quality and accuracy
of all these exams [1].
Images are nowadays an integral part of electronic patient records
and can be reviewed directly by many different health care specialists.
Consequently, it is important that besides the imaging experts (i.e.
radiologists and nuclear medicine physicians), other reviewing clin-
icians are aware that the diagnostic value of a scan is influenced by the
applied imaging protocol and can recognize common artifacts (e.g.
breathing artifacts). More knowledge on this topic will provide clin-
icians tools to communicate with their imaging colleagues to prevent
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image misinterpretation and to select the appropriate image acquisition
protocol.
In two recently performed clinical trials (NTR3628 and
NCT01171170) studying patients with non-small cell lung cancer
(NSCLC) we experienced that, even though specific imaging guidelines
were mandated by the trial protocol, there was a large variability in
imaging parameters. This influenced not only the outcome of the trial
but could also have impact on treatment by their clinical physician
(medical oncologist/pulmonologist). In this manuscript, we describe
the imaging problems encountered in these two trials. Furthermore, we
will provide recommendations to guide clinicians in the interpretation
of medical imaging based on our experience. Our goal is that this will
result in improved clinical care as well as imaging standardization, not
only in future multicenter studies, but also in daily clinical care.
2. Methods
2.1. NVALT12 18F-FDG PET/CT imaging sub-study
In all lung cancer patients eligible for therapy with curative intent,
not only a CE- chest-CT, but also a whole body 18F-FDG-PET is re-
commended [2,3]. The 18F-FDG-PET, performed with a non-diagnostic
low dose CT (LD-CT) for attenuation correction can be extended by an
additional diagnostic CE-CT of the chest (with or without the upper
abdomen and brain).
In the multicenter randomized phase II NVALT12 trial
(NCT01171170) chemo-naïve patients with stage IV non-squamous
NSCLC were treated with paclitaxel-carboplatin-bevacizumab with or
without nitroglycerin patches. For patients in whom an 18F-FDG-PET at
baseline was performed as part of standard work-up, a second study
18F-FDG-PET was performed within three weeks after start of treatment.
The two 18F-FDG-PETs were used for response assessment, and results
have been reported [4]. It was assumed that image acquisition was per
the European Association of Nuclear Medicine (EANM) guidelines for
tumor imaging version 1 as introduced in 2009, therefore no PET
guidelines were added to the protocol [1].
2.2. Study NTR3628: brain imaging
Although patients with brain metastases often have neurological
complaints, 3–21% of neurologically asymptomatic patients with
otherwise stage I–III lung cancer are diagnosed with brain metastases
on MRI [5]. This diagnosis is especially important in patients that are
potentially eligible for therapy with curative intent. A post-gadolinium-
MRI (post-Gd-MRI) is the imaging modality of choice, but when MRI is
contra-indicated or too difficult to arrange within a reasonable time
scale, a diagnostic CE-CT is an acceptable alternative [2,3]. Except for
the recommendation to include Gd-contrast series, no recommenda-
tions are given in the ESMO and NCCN lung cancer guidelines regarding
the minimal requirements for this brain MRI (e.g. applied MRI se-
quences (e.g. T1, T2 FLAIR, diffusion weighted imaging) and minimum
contrast amount) [2,3]. For brain CTs, intravenous administration of
iodine-containing contrast is advised but otherwise no recommenda-
tions are made (e.g. minimum number of mAs and minimum contrast
dose) [2,3].
In the multicenter NTR3628 study, the additional value of a post-
contrast brain MRI was evaluated in stage III (based on 18F-FDG-PET/
CE-CT) NSCLC patients. All patients underwent a dedicated brain CE-CT
as part of the staging whole body 18F-FDG-PET as standard of care [6].
Imaging requirements were: a standard 18F-FDG-PET/CE-CT protocol
that included a diagnostic CE-CT brain, and a 1.5T Gd-MRI brain (1mm
slices, 0.1 mmol/kg gadolinium), with a magnetization transfer contrast
(MTC) pre-pulse to increase sensitivity and an additional post-contrast
FLAIR sequence. MRI parameters were as recommended by an experi-
enced neuro-radiologist (PH) and followed the American College of
Radiology Appropriateness Criteria (ACR AC) [7]. After inclusion of all
patients, CE-CTs and MRIs were per protocol centrally reviewed by PH
for protocol adherence and presence of brain metastases.
3. Results
3.1. NVALT12 18F-FDG PET/CT imaging sub-study
In the imaging analysis sub-study of the NVALT12, 167 baseline
scans and 118 follow-up PET scans for response evaluation were pre-
sent. Only 97 (34%) of the 285 18F-FDG-PETs performed in this study
had an 18F-FDG uptake time as recommended by the EANM. Fifty-four
(19%) scans had both uptake times in agreement with the uniform
protocols for imaging in clinical trials (UPICT) guidelines.
Supplementary material S1 shows the uptake times of the baseline- and
the response scans ranked in ascending order for the baseline scan, only
the uptake times between the red lines can be used for response as-
sessment. The other investigated parameters in this imaging sub-study,
correction factors (attenuation, randoms, scatter) and reconstruction
Fig. 1. a) Baseline 18F-FDG-PET/CT scan of the NCT01171170 trial; b) Response 18F-FDG-PET/CT scan of the same patient, showing that a different SUVmean of the
liver can lead to a visually underestimation of response in the tumor; c) Axial CT image of the brain of the NTR3628 after contrast administration, reconstructed with
a field of view of 500× 500mm with raised arms (note the high level of noise and the streak artifacts due to beam hardening); d) Axial CT image of the brain of the
same patient at approximate the same level, also after contrast administration, reconstructed with a FOV of 200×200mm with the arms lowered. The window and
level setting are identical as well as other acquisition parameters for all imaging, note the difference in image quality.
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settings (method, convolution kernel, matrix size) were assessed in a
quality score.
In this study, 60% (171/285) of the 18F-FDG-PETs had a SUVmean of
the liver within reference values. Fig. 1 shows an example of how a
difference in SUVmean of the liver between the baseline and the response
scan can lead to a visual underestimation of tumor response. Although
we expected a non-compliant SUVmean of the liver for scans with a low
quality score, our results did not show such a relation between the
quality score and SUVmean of the liver [8].
3.2. Study NTR3628: brain imaging
With respect to dedicated brain imaging, imaging related problems
were encountered both during set-up and after central imaging review.
Trial set-up was in 2012 and it was planned to have four hospitals in-
volved, but one did not have a MRI scanner that could meet the re-
quired technical standards and was excluded from participation. Two
other hospitals used MRI protocols that did not meet the required
standards (5 mm instead of 1mm slices, no MTC technique), but they
agreed to update their protocols to be able to participate in the study.
Two-hundred-fifteen neurologically asymptomatic, extracranial stage
III (based on the 18F-FDG-PET-CE-CT) NSCLC patients were included
between December 2012 and July 2016. After central review, it turned
out that in 56 patients (26%) the CE-CT of the brain did not meet the
criteria for a dedicated brain imaging protocol. Remarkably, for these
patients CE-CT brain results were reported in the radiology report
without noting the limitations of the study. Problems with these brain
CE-CTs were the field of view ((FOV), adjusted to the thorax, but not to
the brain) and the arm position (above the head instead of at thorax
level, see Fig. 1).
4. Discussion
Imaging techniques have significantly evolved over the last years
and have become more sensitive for the detection of subtle abnormal-
ities. In (lung) cancer guidelines, recommendations regarding imaging
techniques are made and even separate detailed 18F-FDG-PET-(CT) re-
commendations exist [2,3]. However, no recommendations are made
on the minimal technical requirements, resulting in a large variation in
accuracy. Therefore, there is a large variability in imaging parameters
and scanners, which can influence not only the clinical trial outcome
but also the clinical interpretation by the treating physician. In this
manuscript, we report on two trials in which problems were en-
countered due to variation in applied imaging protocols, which people
did not realize beforehand. In NTR3628, after central imaging review, it
turned out that the CE-CTs brain of several included patients suffered
from unreported serious flaws. In this specific trial, the non-diagnostic
CE-CT had no clinical consequences, as all patients underwent a post-
Gd-MRI. However, when limitations of an examination are not re-
cognized nor reported, this can have serious consequences (see
Table 1). Depending on geographical location and institution, in
48–62% of patients a CE-CT is performed instead of a post-Gd-MRI to
screen for brain metastases [9]. Although not reported in CE-CT ima-
ging guidelines, is the importance of the patient position: it should be
reproducible and standardized, and it matters what the FOV and patient
position is. The FOV should be adjusted to the size of the head and arms
should be at thorax level to reduce artifacts and acquire diagnostic
images (see Fig. 1). Furthermore, just the application of iodine contrast
administration does not make the CT-brain diagnostic: timing of the
scan relative to contrast injection and the amount of contrast material
injected are important. For tumor response assessment using 18F-FDG-
PET, it is important that scans are performed with the same acquisition
and reconstruction settings as baseline. Because varying uptake times
lead to variations in measured SUV, a larger uptake time will result in a
higher SUV because tumor SUV increases over time. In response as-
sessment studies, changes in SUV over time are the parameter of in-
terest and therefore differences in uptake times between repeated scans
can lead to scan misinterpretation. Variability in uptake times of the
baseline as well as the response scan made that only 46 scans could be
used for early response assessment in the NVALT12 sub-study. A study
of Kuhnert et al. [10] showed that for settings like the injected activity
and the uptake time the SUVmean of the liver could be used for quality
assessment in compliance with the EANM guideline. This means that in
the NVALT12 sub-study the large variability in SUVmean of the liver is
most probably caused by the differences in uptake time (although a
treatment effect cannot be excluded). In the NVALT12 sub-study no
relation between deviation in image parameters, reflected in the quality
score, and the SUVmean of the liver was reported. The SUVmean of the
liver can therefore not exclude all quality issues, although, it could be
used as a quick quality control with reference values between 1.3 and
2.5. Our recommendations for clinicians regarding repeated 18F-FDG-
PET imaging for response assessment are to try to use the same
Table 1
Recommendations and consequences for a quality check of repeated 18F-FDG-PET scans, brain CE-CT scans and brain MRI scans based on current guidelines, expert
opinion and results of two clinical trials.
Image Modality Recommendations Consequences when not performed
MRI brain T2 Combination of sequences gives a complete overview, missing a sequence can lead
to a wrong diagnosis (e.g. benign vs. malignant)T2-FLAIR
DWI
T1 before contrast
T1 post contrast
Axial slice thickness between 3mm and 5mm With thicker slices small lesions can be missed
Minimal 1.5 T Too low signal-noise ratio and lower resolution can lead to missing small lesions.
CE-CT brain Field-of-view should be set to head Artefacts
Arms of the patients at thorax level Artefacts
Delayed imaging Less contrast in the head
Higher contrast dose Lesion less visible
18F-FDG-PET/CT Identical scanner Different acquisition parameters
Patient position similar to baseline scan Difficult measuring same region of interest
Identical PET acquisition repeated scans Different spatial resolution, different SUV values
Identical PET reconstruction repeated scans Different spatial resolution, different SUV values
Uptake times >55min; < 75min Lower, higher SUV values
Δ uptake times between repeated scans < 15min SUV value deviations
DICOM header/CRF contains: injection time, scan time, patient weight,
radionuclide dose, SUV conversion tag
SUV value cannot be calculated
Mean SUV liver between 1.3 and 2.5 Misleading visual interpretation
If any of the recommendations is not met, please consult your nuclear medicine or radiology expert.
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scanning parameters as for the first scan, or check if the same scan
parameters are used as in the previous scan. Scans with an uptake time
less than 55min or more than 75min cannot reliable be used and
checking the SUVmean of liver can be used as quality assurance. For data
analysis it is important that all scan parameters are noted in the DICOM
header, but at least injection time, scan time, patient’s body weight,
radionuclide dose and the SUV conversion tag should be present. An
example of a DICOM header with the minimum required tags is shown
in the supplementary material S2. For brain CE-CT combined with the
18F-FDG-PET scan, we recommend that the clinician checks the head
FOV, the patient arm position and the contrast dose and timing.
For MRI, at least a T2-weighted sequence, a T2-FLAIR and a T1-
weighted sequence pre- and post-contrast should be performed. See for
an overview of these recommendations Table 1. If any of the re-
commendations cannot be met it is advised to consult an imaging ex-
pert.
In addition, radiologists need to be informed about the indication
for the requested scan and therefore clinicians must provide all clinical
information that is important to determine the optimal imaging pro-
tocol to apply. Next to that, for non-imaging clinicians it is important to
evaluate whether the applied imaging protocol is indeed adequate for
the requested purpose. Our quality recommendations will potentially
lead to a more uniform clinical interpretation and could be helpful
during multidisciplinary meetings. These recommendations should
preferably be tested prospectively.
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